{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:45:48Z","timestamp":1774053948041,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High rates of placebo response are increasingly implicated in failed autism spectrum disorder (ASD) clinical trials. Despite this, there are limited investigations of placebo response in ASD. We sought to identify baseline predictors of placebo response and quantify their influence on clinical scales of interest for three harmonized randomized clinical trials of balovaptan, a V1a receptor antagonist. We employed a two-step approach to identify predictors of placebo response on the Vineland-II two-domain composite (2DC) (primary outcome and a caregiver measure) and Clinical Global Impression (CGI) scale (secondary outcome and a clinician measure). The initial candidate predictor set of variables pertained to participant-level, site-specific, and protocol-related factors. Step 1 aimed to identify influential predictors of placebo response using Least Absolute Shrinkage and Selection Operator (LASSO) regression, while Step 2 quantified the influence of predictors via linear regression. Results were validated through statistical bootstrapping approaches with 500 replications of the analysis dataset. The pooled participant-level dataset included individuals with ASD aged 5 to 62 years (mean age 21 [SD 10]), among which 263 and 172 participants received placebo at Weeks 12 and 24, respectively. Although no influential predictors were identified for CGI, findings for Vineland-II 2DC are robust and informative. Decreased placebo response was predicted by higher baseline Vineland-II 2DC (i.e., more advanced adaptive function), longer trial duration, and European (vs United States) sites, while increased placebo response was predicted by commercial (vs academic) sites, attention deficit hyperactivity disorder and depression. Identification of these factors may be useful in anticipating and mitigating placebo response in drug development efforts in ASD and across developmental and psychiatric conditions.<\/jats:p>","DOI":"10.1038\/s41386-023-01573-9","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T13:03:17Z","timestamp":1681304597000},"page":"1201-1216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Predictors of placebo response in three large clinical trials of the V1a receptor antagonist balovaptan in autism spectrum disorder"],"prefix":"10.1038","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7738-8344","authenticated-orcid":false,"given":"Russell","family":"Tobe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Gleissl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8633-5009","authenticated-orcid":false,"given":"Simona","family":"Rossomanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Veenstra-VanderWeele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"1573_CR1","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.21037\/tp.2019.09.09","volume":"9","author":"H Hodges","year":"2020","unstructured":"Hodges H, Fealko C, Soares N. Autism spectrum disorder: definition, epidemiology, causes, and clinical evaluation. Transl Pediatr. 2020;9:S55\u2013S65.","journal-title":"Transl Pediatr"},{"key":"1573_CR2","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/s41390-021-01465-y","volume":"91","author":"N Malik-Soni","year":"2021","unstructured":"Malik-Soni N, Shaker A, Luck H, Mullin AE, Wiley RE, Lewis MES, et al. Tackling healthcare access barriers for individuals with autism from diagnosis to adulthood. Pediatr Res. 2021;91:1028\u201335.","journal-title":"Pediatr Res"},{"key":"1573_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6904a1","volume":"69","author":"MJ Maenner","year":"2020","unstructured":"Maenner MJ, Shaw KA, Baio J, Washington A, Patrick M, DiRienzo M, et al. Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2016. MMWR Surveill Summ. 2020;69:1\u201312.","journal-title":"MMWR Surveill Summ"},{"key":"1573_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11920-021-01292-2","volume":"23","author":"RP Thom","year":"2021","unstructured":"Thom RP, Pereira JA, Sipsock D, McDougle CJ. Recent updates in psychopharmacology for the core and associated symptoms of autism spectrum disorder. Curr Psychiatry Rep. 2021;23:1\u20139.","journal-title":"Curr Psychiatry Rep"},{"key":"1573_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S2215-0366(21)00429-6","volume":"9","author":"S Jacob","year":"2022","unstructured":"Jacob S, Veenstra-VanderWeele J, Murphy D, McCracken J, Smith J, Sanders K, et al. Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial. Lancet Psychiatry. 2022;9:199\u2013210.","journal-title":"Lancet Psychiatry"},{"key":"1573_CR6","doi-asserted-by":"publisher","first-page":"eaat7838","DOI":"10.1126\/scitranslmed.aat7838","volume":"11","author":"F Bolognani","year":"2019","unstructured":"Bolognani F, Del Valle Rubido M, Squassante L, Wandel C, Derks M, Murtagh L, et al. A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Sci Transl Med. 2019;11:eaat7838.","journal-title":"Sci Transl Med"},{"key":"1573_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13229-020-00372-z","volume":"11","author":"S Siafis","year":"2020","unstructured":"Siafis S, \u00c7iray O, Schneider-Thoma J, Bighelli I, Krause M, Rodolico A, et al. Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis. Mol Autism. 2020;11:66.","journal-title":"Mol Autism"},{"key":"1573_CR8","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamapsychiatry.2022.1717","volume":"79","author":"E Hollander","year":"2022","unstructured":"Hollander E, Jacob S, Jou R, McNamara N, Sikich L, Tobe R, et al. Balovaptan vs placebo for social communication in childhood autism spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2022;79:760\u20139.","journal-title":"JAMA Psychiatry"},{"key":"1573_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13229-022-00488-4","volume":"13","author":"S Siafis","year":"2022","unstructured":"Siafis S, \u00c7iray O, Wu H, Schneider-Thoma J, Bighelli I, Krause M, et al. Pharmacological and dietary supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis. Mol Autism. 2022;13:10.","journal-title":"Mol Autism"},{"key":"1573_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12264-017-0100-y","volume":"33","author":"A Masi","year":"2017","unstructured":"Masi A, DeMayo MM, Glozier N, Guastella AJ. An overview of autism spectrum disorder, heterogeneity and treatment options. Neurosci Bull. 2017;33:183\u201393.","journal-title":"Neurosci Bull"},{"key":"1573_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/mpr.1466","volume":"24","author":"TS Brugha","year":"2015","unstructured":"Brugha TS, Doos L, Tempier A, Einfeld S, Howlin P. Outcome measures in intervention trials for adults with autism spectrum disorders; a systematic review of assessments of core autism features and associated emotional and behavioural problems. Int J Methods Psychiatr Res. 2015;24:99\u2013115.","journal-title":"Int J Methods Psychiatr Res"},{"key":"1573_CR12","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1177\/1362361314542955","volume":"19","author":"E Anagnostou","year":"2015","unstructured":"Anagnostou E, Jones N, Huerta M, Halladay AK, Wang P, Scahill L, et al. Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder. Autism. 2015;19:622\u201336.","journal-title":"Autism"},{"key":"1573_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fnint.2020.00016","volume":"14","author":"JC McPartland","year":"2020","unstructured":"McPartland JC, Bernier RA, Jeste SS, Dawson G, Nelson CA, Chawarska K, et al. The Autism Biomarkers Consortium for Clinical Trials (ABC-CT): scientific context, study design, and progress toward biomarker qualification. Front Integr Neurosci. 2020;14:16.","journal-title":"Front Integr Neurosci"},{"key":"1573_CR14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s10803-015-2562-y","volume":"46","author":"E Moricke","year":"2016","unstructured":"Moricke E, Buitelaar JK, Rommelse NNJ. Do we need multiple informants when assessing autistic traits? The degree of report bias on offspring, self, and spouse ratings. J Autism Dev Disord. 2016;46:164\u201375.","journal-title":"J Autism Dev Disord"},{"key":"1573_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1136\/bmjspcare-2019-002163","volume":"10","author":"R Roji","year":"2020","unstructured":"Roji R, Stone P, Ricciardi F, Candy B. Placebo response in trials of drug treatments for cancer-related fatigue: a systematic review, meta-analysis and meta-regression. BMJ Support Palliat Care. 2020;10:385.","journal-title":"BMJ Support Palliat Care"},{"key":"1573_CR16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S2215-0366(14)00092-3","volume":"2","author":"K Weimer","year":"2015","unstructured":"Weimer K, Colloca L, Enck P. Placebo effects in psychiatry: mediators and moderators. Lancet Psychiatry. 2015;2:246\u201357.","journal-title":"Lancet Psychiatry"},{"key":"1573_CR17","doi-asserted-by":"crossref","unstructured":"Duarte GS, Mainoli B, Rodrigues FB, Rato F, Machado T, Ferreira JJ, et al. Placebo response in chronic peripheral neuropathic pain trials: systematic review and meta-analysis. medRxiv. 2022.02.18.22271196.","DOI":"10.1101\/2022.02.18.22271196"},{"key":"1573_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01787-4","volume":"18","author":"C Lin","year":"2020","unstructured":"Lin C, Cai X, Yang W, Lv F, Nie L, Ji L. Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. BMC Med. 2020;18:322.","journal-title":"BMC Med"},{"key":"1573_CR19","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.jash.2016.10.009","volume":"10","author":"M Wilhelm","year":"2016","unstructured":"Wilhelm M, Winkler A, Rief W, Doering BK. Effect of placebo groups on blood pressure in hypertension: a meta-analysis of beta-blocker trials. J Am Soc Hypertens. 2016;10:917\u201329.","journal-title":"J Am Soc Hypertens"},{"key":"1573_CR20","doi-asserted-by":"publisher","first-page":"101685","DOI":"10.1016\/j.eclinm.2022.101685","volume":"54","author":"YH Chin","year":"2022","unstructured":"Chin YH, Ng CH, Chew NW, Kong G, Lim WH, Tan DJH, et al. The placebo response rate and nocebo events in obesity pharmacological trials. A systematic review and meta-analysis. EClinicalMedicine. 2022;54:101685.","journal-title":"EClinicalMedicine"},{"key":"1573_CR21","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.cgh.2018.06.011","volume":"17","author":"MAT Han","year":"2019","unstructured":"Han MAT, Altayar O, Hamdeh S, Takyar V, Rotman Y, Etzion O, et al. Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17:616\u2013629.e626.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1573_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/cap.2015.0146","volume":"27","author":"MG Aman","year":"2017","unstructured":"Aman MG, Findling RL, Hardan AY, Hendren RL, Melmed RD, Kehinde-Nelson O, et al. Safety and efficacy of memantine in children with autism: randomized, placebo-controlled study and open-label extension. J Child Adolesc Psychopharmacol. 2017;27:403\u201312.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1573_CR23","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1038\/s41380-018-0097-2","volume":"25","author":"H Yamasue","year":"2020","unstructured":"Yamasue H, Okada T, Munesue T, Kuroda M, Fujioka T, Uno Y, et al. Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial. Mol Psychiatry. 2020;25:1849\u201358.","journal-title":"Mol Psychiatry"},{"key":"1573_CR24","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1001\/jamapediatrics.2013.2698","volume":"167","author":"BH King","year":"2013","unstructured":"King BH, Dukes K, Donnelly CL, Sikich L, McCracken JT, Scahill L, et al. Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial. JAMA Pediatr. 2013;167:1045\u201352.","journal-title":"JAMA Pediatr"},{"key":"1573_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.143","volume":"5","author":"A Masi","year":"2015","unstructured":"Masi A, Lampit A, Glozier N, Hickie IB, Guastella AJ. Predictors of placebo response in pharmacological and dietary supplement treatment trials in pediatric autism spectrum disorder: a meta-analysis. Transl Psychiatry. 2015;5:e640.","journal-title":"Transl Psychiatry"},{"key":"1573_CR26","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/ije\/dyz032","volume":"48","author":"RA Hughes","year":"2019","unstructured":"Hughes RA, Heron J, Sterne JAC, Tilling K. Accounting for missing data in statistical analyses: multiple imputation is not always the answer. Int J Epidemiol. 2019;48:1294\u2013304.","journal-title":"Int J Epidemiol"},{"key":"1573_CR27","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1176\/appi.ajp.2012.12040474","volume":"170","author":"BR Rutherford","year":"2013","unstructured":"Rutherford BR, Roose SP. A model of placebo response in antidepressant clinical trials. Am J Psychiatry. 2013;170:723\u201333.","journal-title":"Am J Psychiatry"},{"key":"1573_CR28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc Ser B. 1996;58:267\u201388.","journal-title":"J R Stat Soc Ser B."},{"key":"1573_CR29","doi-asserted-by":"crossref","unstructured":"Harrell Jr FE. Regression modeling strategies with applications to linear models, logistic and ordinal regression, and survival analysis. 2nd ed. Springer Cham: New York, NY; 2015.","DOI":"10.1007\/978-3-319-19425-7"},{"key":"1573_CR30","doi-asserted-by":"crossref","unstructured":"James G, Witten D, Hastie T, Tibshirani R. An introduction to statistical learning with applications in R. Springer: New York, NY; 2013.","DOI":"10.1007\/978-1-4614-7138-7"},{"key":"1573_CR31","doi-asserted-by":"publisher","first-page":"g7594","DOI":"10.1136\/bmj.g7594","volume":"350","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350:g7594.","journal-title":"BMJ."},{"key":"1573_CR32","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/aur.1874","volume":"11","author":"CH Chatham","year":"2018","unstructured":"Chatham CH, Taylor KI, Charman T, Liogier D\u2019ardhuy X, Eule E, Fedele A, et al. Adaptive behavior in autism: minimal clinically important differences on the Vineland-II. Autism Res. 2018;11:270\u201383.","journal-title":"Autism Res"},{"key":"1573_CR33","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41380-021-01134-w","volume":"27","author":"SV Faraone","year":"2022","unstructured":"Faraone SV, Newcorn JH, Cipriani A, Brandeis D, Kaiser A, Hohmann S, et al. Placebo and nocebo responses in randomised, controlled trials of medications for ADHD: a systematic review and meta-analysis. Mol Psychiatry. 2022;27:212\u20139.","journal-title":"Mol Psychiatry"},{"key":"1573_CR34","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.4088\/JCP.v67n1111","volume":"67","author":"DJ Stein","year":"2006","unstructured":"Stein DJ, Baldwin DS, Dolberg OT, Despiegel N, Bandelow B. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry. 2006;67:1741\u20136.","journal-title":"J Clin Psychiatry"},{"key":"1573_CR35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000365248","volume":"61","author":"K Weimer","year":"2015","unstructured":"Weimer K, Colloca L, Enck P. Age and sex as moderators of the placebo response \u2013 an evaluation of systematic reviews and meta-analyses across medicine. Gerontology. 2015;61:97\u2013108.","journal-title":"Gerontology."},{"key":"1573_CR36","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/pr.2013.66","volume":"74","author":"K Weimer","year":"2013","unstructured":"Weimer K, Gulewitsch MD, Schlarb AA, Schwille-Kiuntke J, Klosterhalfen S, Enck P. Placebo effects in children: a review. Pediatr Res. 2013;74:96\u2013102.","journal-title":"Pediatr Res"},{"key":"1573_CR37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/1362361317733113","volume":"23","author":"M Pathak","year":"2019","unstructured":"Pathak M, Bennett A, Shui AM. Correlates of adaptive behavior profiles in a large cohort of children with autism: The Autism Speaks Autism Treatment Network registry data. Autism. 2019;23:87\u201399.","journal-title":"Autism"},{"key":"1573_CR38","first-page":"1","volume":"27","author":"JB Williams","year":"2012","unstructured":"Williams JB, Popp D, Kobak KA, Detke MJ. P-640 - The power of expectation bias. Eur Psychiatry. 2012;27:1.","journal-title":"Eur Psychiatry"},{"key":"1573_CR39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/ijnp\/pyab054","volume":"25","author":"X Castells","year":"2022","unstructured":"Castells X, Saez M, Barcheni M, Cunill R, Serrano D, L\u00f3pez B, et al. Placebo response and its predictors in attention deficit hyperactivity disorder: a meta-analysis and comparison of meta-regression and MetaForest. Int J Neuropsychopharmacol. 2022;25:26\u201335.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1573_CR40","doi-asserted-by":"publisher","first-page":"e041349","DOI":"10.1136\/bmjopen-2020-041349","volume":"11","author":"BD Jones","year":"2021","unstructured":"Jones BD, Weissman CR, Razza LB, Ishrat Husain M, Brunoni AR, Daskalakis ZJ. Protocol for a systematic review and meta-analysis of the placebo response in treatment-resistant depression: comparison of multiple treatment modalities. BMJ Open. 2021;11:e041349.","journal-title":"BMJ Open"},{"key":"1573_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/schbul\/sbx192","volume":"45","author":"D Fraguas","year":"2019","unstructured":"Fraguas D, Diaz-Caneja CM, Pina-Camacho L, Umbricht D, Arango C. Predictors of placebo response in pharmacological clinical trials of negative symptoms in schizophrenia: a meta-regression analysis. Schizophr Bull. 2019;45:57\u201368.","journal-title":"Schizophr Bull"},{"key":"1573_CR42","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1089\/cap.2015.0192","volume":"26","author":"ET Dobson","year":"2016","unstructured":"Dobson ET, Strawn JR. Placebo response in pediatric anxiety disorders: implications for clinical trial design and interpretation. J Child Adolesc Psychopharmacol. 2016;26:686\u201393.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1573_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13229-022-00505-6","volume":"13","author":"S Jacob","year":"2022","unstructured":"Jacob S, Anagnostou E, Hollander E, Jou R, McNamara N, Sikich L, et al. Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program. Mol Autism. 2022;13:25.","journal-title":"Mol Autism"},{"key":"1573_CR44","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/ije\/dyy076","volume":"47","author":"G Salanti","year":"2018","unstructured":"Salanti G, Chaimani A, Furukawa TA, Higgins JPT, Ogawa Y, Cipriani A, et al. Impact of placebo arms on outcomes in antidepressant trials: systematic review and meta-regression analysis. Int J Epidemiol. 2018;47:1454\u201364.","journal-title":"Int J Epidemiol"},{"key":"1573_CR45","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S2215-0366(16)30307-8","volume":"3","author":"TA Furukawa","year":"2016","unstructured":"Furukawa TA, Cipriani A, Atkinson LZ, Leucht S, Ogawa Y, Takeshima N, et al. Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. Lancet Psychiatry. 2016;3:1059\u201366.","journal-title":"Lancet Psychiatry"},{"key":"1573_CR46","first-page":"28","volume":"4","author":"JT Busner","year":"2007","unstructured":"Busner JT, Targum SD. The Clinical Global Impressions scale. Psychiatry (Edgmont). 2007;4:28\u201337.","journal-title":"Psychiatry (Edgmont)"},{"key":"1573_CR47","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1002\/aur.1798","volume":"10","author":"RM Jones","year":"2017","unstructured":"Jones RM, Carberry C, Hamo A, Lord C. Placebo\u2010like response in absence of treatment in children with autism. Autism Res. 2017;10:1567\u201372.","journal-title":"Autism Res."},{"key":"1573_CR48","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40122-017-0071-8","volume":"6","author":"E Frisaldi","year":"2017","unstructured":"Frisaldi E, Shaibani A, Benedetti F. Why we should assess patients\u2019 expectations in clinical trials. Pain Ther. 2017;6:107\u201310.","journal-title":"Pain Ther"},{"key":"1573_CR49","unstructured":"FDA News. Roche\u2019s autism drug balovaptan granted breakthrough therapy designation. 2018. https:\/\/www.fdanews.com\/articles\/185437-roches-autism-drug-balovaptan-granted-breakthrough-therapy-designation. Accessed February 24 2023."},{"key":"1573_CR50","first-page":"12","volume":"16","author":"ME Whitlock","year":"2019","unstructured":"Whitlock ME, Woodward PW, Alexander RC. Is high placebo response really a problem in depression trials? A critical re-analysis of depression studies. Innov Clin Neurosci. 2019;16:12\u20137.","journal-title":"Innov Clin Neurosci"},{"key":"1573_CR51","first-page":"135","volume":"16","author":"A Klin","year":"2018","unstructured":"Klin A. Biomarkers in autism spectrum disorder: challenges, advances, and the need for biomarkers of relevance to public health. Focus (Am Psychiatr Publ). 2018;16:135\u201342.","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"1573_CR52","doi-asserted-by":"publisher","first-page":"792","DOI":"10.21037\/atm.2019.11.53","volume":"7","author":"RE Frye","year":"2019","unstructured":"Frye RE, Vassall S, Kaur G, Lewis C, Karim M, Rossignol D. Emerging biomarkers in autism spectrum disorder: a systematic review. Ann Transl Med. 2019;7:792.","journal-title":"Ann Transl Med"},{"key":"1573_CR53","doi-asserted-by":"publisher","first-page":"e11365","DOI":"10.2196\/11365","volume":"6","author":"A Bangerter","year":"2019","unstructured":"Bangerter A, Manyakov NV, Lewin D, Boice M, Skalkin A, Jagannatha S, et al. Caregiver daily reporting of symptoms in autism spectrum disorder: observational study using web and mobile apps. JMIR Ment Health. 2019;6:e11365.","journal-title":"JMIR Ment Health"},{"key":"1573_CR54","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s40291-022-00600-7","volume":"26","author":"AR Jensen","year":"2022","unstructured":"Jensen AR, Lane AL, Werner BA, McLees SE, Fletcher TS, Frye RE. Modern biomarkers for autism spectrum disorder: future directions. Mol Diagn Ther. 2022;26:483\u201395.","journal-title":"Mol Diagn Ther"},{"key":"1573_CR55","doi-asserted-by":"crossref","unstructured":"Gromova M, Vaggelas A, Dallmann G, Seimetz D. Biomarkers: opportunities and challenges for drug development in the current regulatory landscape. Biomark Insights. 2020;15:1177271920974652.","DOI":"10.1177\/1177271920974652"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-023-01573-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-023-01573-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-023-01573-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T04:25:03Z","timestamp":1729225503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-023-01573-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1573"],"URL":"https:\/\/doi.org\/10.1038\/s41386-023-01573-9","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"assertion":[{"value":"21 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EH has received research grants from the Department of Defense, Food and Drug Administration, GW Pharma, and F. Hoffmann-La Roche Ltd; editorial stipends from Elsevier; and served on scientific advisory boards for GW Pharma and F. Hoffmann-La Roche Ltd. RT has received grant support from Axial Therapeutics, Janssen, and F. Hoffmann-La Roche Ltd; and has attended advisory boards for F. Hoffmann-La Roche Ltd. JVV has received research support from NIH, the Simons Foundation, Health Canada, F. Hoffmann-La Roche Ltd, Janssen, Acadia, MapLight, and Yamo Pharmaceuticals; royalties from Springer and Wiley; has attended advisory boards for Roche; and serves on the medical and\/or scientific advisory boards for Autism Speaks, the Simons Foundation Autism Research Initiative, and the Brain Behavior Research Foundation. JS, YZ, TG, and SR are employees of F. Hoffmann-La Roche Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}